P-21 Peptide Vial
The P-21 peptide, also known as CIP1/WAF1, is a critical regulator of cell cycle progression with significant implications in various fields, including neurology, oncology, and medical aesthetics.
This multifaceted peptide plays a pivotal role in inhibiting the activity of cyclin-dependent kinase (CDK) complexes, such as CDK2, CDK1, and CDK4/6, thereby exerting control over cell division and proliferation. In the context of neurology, New Zealand studies have shown that P-21 may have therapeutic potential in enhancing neurogenesis and memory, offering promise in addressing conditions associated with neurocognitive disorders and traumatic brain injuries.
Furthermore, P-21’s involvement in cancer research is noteworthy, particularly in the treatment of prostate cancer. New Zealand Research suggests that thermally targeted P-21 peptides have the potential to enhance the efficacy of treatments for prostate cancer, presenting a novel avenue for improving therapeutic outcomes in one of the most common malignancies affecting men.
Moreover, the peptide’s role in enhancing learning and memory, promoting neurogenesis, and improving synaptic plasticity in mice underscores its significance in neurological research. With its diverse applications from neurogenesis to cancer therapy, the P-21 peptide represents a compelling area of study with far-reaching implications across multiple disciplines.
Benefits of P-21 Peptide Vial
- Enhanced neurogenesis and memory support, potentially beneficial for addressing neurocognitive disorders and traumatic brain injuries.
- Clinical studies have suggested that the P-21 peptide vial can provide improved learning, memory, neurogenesis, and synaptic plasticity, offering potential applications in cognitive enhancement and neurological research.
- Inhibition of cyclin-dependent kinase (CDK) activity, contributing to cell cycle regulation and potential implications in cancer therapy.
- Potential use in medical aesthetics and biohacking, implying applications in anti-aging and aesthetic treatments.
- Identification of peptide domains that alter conformation in response to oncogenic amino acid substitutions, indicating potential relevance in New Zealand cancer research and targeted therapies.
- Selective blocking of the oncogenic RAS-p21 protein in ras-induced cancers, suggesting potential as a therapeutic target in cancer treatment.
- Enhanced tumour accumulation, implying potential applications in targeted drug delivery and cancer therapy.
- High-affinity binding to PCNA via a 310-helical binding conformation, suggesting potential implications in DNA repair and related processes.
References:
[1] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC4963295/
[2] https://pubmed.ncbi.nlm.nih. gov/24113592/
[3] https://www.sciencedirect.com/ science/article/pii/S00145793 1000520X
ALL PRODUCT INFORMATION AND ARTICLES ON THIS SITE ARE FOR EDUCATIONAL PURPOSES ONLY
DISCLAIMER: All products sold by PharmaGrade.Store are for research and laboratory use only. These products are not designed for use or consumption by humans or animals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such. By purchasing from our Website the buyer accepts and acknowledges the risks involved with handling of these products. All articles and product information provided on this Website are for informational and educational purposes only. Handling and use of these products should be restricted to suitably qualified professionals.
